Morgane is responsible for the development and implementation of communications and public affairs programs at IFPMA.
Translating complex notions into clear-cut communications, she develops tools to facilitate understanding of the pharmaceutical industry’s business model and raise awareness about its innovative collaborations to improve people’s health wherever they live.
Morgane brings a great deal of knowledge across disciplines, from corporate communications strategy, media interaction, and stakeholder engagement through digital campaigns, internal communications, and engagement with IFPMA membership.
She also builds relationships, platforms, and alliances with actors operating in the global health community to facilitate information exchange and foster dialogue to tackle global health challenges.
Before joining IFPMA, Morgane was a Project Assistant at a global event and communications group, MCI, in Geneva. Prior to this, she interned at the French Ministry of Defense.
Morgane holds a Master in Languages and Literature from the University of Geneva and a post-graduate degree in Special Events Communication from the Advancia School in Paris.
Sharing testimonials telling the human stories of people who were working on solutions to tackle the COVID-19 pandemic was one of the most humbling and rewarding experiences I’ve had at IFPMA.
More from Morgane
The biopharmaceutical industry continues to innovate and push science forward to manage the COVID-19 pandemic and be better prepared for future global health threats
Viruses don’t stand still. And neither do we. It’s been almost two years since the administration of the first COVID-19 vaccine in December 2020 and as of September 2022, more than two thirds of people worldwide had received at least one COVID-19 vaccine dose.
Vaccines can help make a better life possible for everyone
Vaccines are one of the most effective and cost-efficient medical technologies ever developed. Except for clean water, nothing has had a larger effect on global health than vaccines, especially for children.
The biopharmaceutical industry continues to innovate to find new and improved COVID-19 solutions
It’s been over two years since the biopharmaceutical industry committed to playing the greatest possible role in the global response to COVID-19.